Brief: AB Science Announces A Voluntary Hold In The Clinical Studies Of Masitinib Worldwide

AB Science SA

01/06/2021 06:08

June 1 (Reuters) - AB Science SA  ABS.PA :
    * AB SCIENCE ANNOUNCES A VOLUNTARY HOLD IN THE CLINICAL
STUDIES OF
MASITINIB WORLDWIDE
    * DECISION FOLLOWS CONSULTATION WITH FRENCH REGULATORY
AUTHORITIES
(ANSM) AND OTHER REGULATORY AGENCIES
    * DECISION RELEVANT TO: PHASE 3 IN MASTOCYTOSIS (AB15003),
PHASE 3
IN AMYOTROPHIC LATERAL SCLEROSIS (AB19001) AND PHASE 2 IN COVID
(AB20001)
    * IDENTIFIED A POTENTIAL RISK OF ISCHEMIC HEART DISEASE WITH
MASITINIB
    * WORKING CLOSELY WITH ANSM AND OTHER REGULATORY AGENCIES TO
COMPLETE NECESSARY ADDITIONAL ANALYSES
    * HAS FILED OR WILL FILE WITHOUT DELAY A REQUEST FOR A
TEMPORARY
STUDY HOLD IN ALL COUNTRIES WHERE THESE STUDIES ARE ONGOING

Source text for Eikon:  ID:nGNEcMV9J 
Further company coverage:  ABS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))